CSPC Pharmaceutical Buys 13.8 Million Shares for 2026 Award Scheme
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.
CSPC Pharmaceutical Group has disclosed that, under its 2026 Restricted Share Award Scheme, a trustee purchased 13.8 million shares on the market on June 3, 2026, representing about 0.12% of the company’s issued share capital. The shares, acquired at an average price of roughly HK$7.1966 for a total consideration of about HK$99.3 million, will be held in trust for selected participants under the scheme.
The board retains full discretion to decide how many shares will ultimately be awarded to eligible participants and whether further on‑market purchases will be made under the 2026 scheme. This move underscores CSPC’s use of equity‑based incentives to align management and employee interests with shareholders, potentially supporting talent retention and long‑term corporate performance.
The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on the research, development, manufacture and sale of pharmaceutical products, serving healthcare markets in China and internationally through a diversified portfolio of medicines and related therapies.
Average Trading Volume: 94,587,264
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.08B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.
